Evidence map›Paper›PMID 8164686›Full record

ArticleMolecular and cellular biology1994

The DNA-bending protein HMG-1 enhances progesterone receptor binding to its target DNA sequences.

S A Oñate, P Prendergast, J P Wagner, M Nissen, R Reeves, D E Pettijohn, D P Edwards

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
14.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 201 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. High-Mobility Group Box-1 and Liver Disease.Hepatology communications · 2018
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. HMGB1 silence could promote MCF-7 cell apoptosis and inhibit invasion and metastasis.International journal of clinical and experimental pathology · 2015
    Article
  12. HMGB1 in health and disease.Molecular aspects of medicine · 2014
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

S A OñateDepartment of Pathology, University of Colorado Cancer Center, Denver 80262.
P Prendergast
J P Wagner
M Nissen
R Reeves
D E Pettijohn
D P Edwards
University of Colorado Cancer Center · USApplied BioPhysics (United States) · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
PROGESTERONE RECEPTOR INTERACTIONR01CA046938 · NCI · UNIVERSITY OF COLORADO DENVER · PI EDWARDS, DEAN P · 1988 to 2013
$3.3M
PACKING OF DNA IN CHROMOSOMESR01GM018243 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI PETTIJOHN, DAVID E · 1985 to 1994
–
NCI NIH HHS CA46938NCI NIH HHS P30CA46934NIGMS NIH HHS GM18243
6 · The paper itself

Abstract

Steroid hormone receptors are ligand-dependent transcriptional activators that exert their effects by binding as dimers to cis-acting DNA sequences termed hormone response elements. When human progesterone receptor (PR), expressed as a full-length protein in a baculovirus system, was purified to homogeneity, it retained its ability to bind hormonal ligand and to dimerize but exhibited a dramatic loss in DNA binding activity for specific progesterone response elements (PREs). Addition of nuclear extracts from several cellular sources restored DNA binding activity, suggesting that PR requires a ubiquitous accessory protein for efficient interaction with specific DNA sequences. Here we have demonstrated that the high-mobility-group chromatin protein HMG-1, as a highly purified protein, dramatically enhanced binding of purified PR to PREs in gel mobility shift assays. This effect appeared to be highly selective for HMG-1, since a number of other nonspecific proteins failed to enhance PRE binding. Moreover, HMG-1 was effective when added in stoichiometric amounts with receptor, and it was capable of enhancing the DNA binding of both the A and B amino-terminal variants of PR. The presence of HMG-1 measurably increased the binding affinity of purified PR by 10-fold when a synthetic palindromic PRE was the target DNA. The increase in binding affinity for a partial palindromic PRE present in natural target genes was greater than 10-fold. Coimmunoprecipitation assays using anti-PR or anti-HMG-1 antibodies demonstrated that both PR and HMG-1 are present in the enhanced complex with PRE. HMG-1 protein has two conserved DNA binding domains (A and B), which recognize DNA structure rather than specific sequences. The A- or B-box domain expressed and purified from Escherichia coli independently stimulated the binding of PR to PRE, and the B box was able to functionally substitute for HMG-1 in enhancing PR binding. DNA ligase-mediated ring closure assays demonstrated that both the A and B binding domains mediate DNA flexure. It was also demonstrated in competition binding studies that the intact HMG-1 protein binds to tightly curved covalently closed or relaxed DNA sequences in preference to the same sequence in linear form. The finding that enhanced PRE binding was intrinsic to the HMG-1 box, combined with the demonstration that HMG-1 or its DNA binding boxes can flex DNA, suggests that HMG-1 facilitates the binding of PR by inducing a structural change in the target DNA.

Indexed as

AnimalsBaculoviridaeBinding, CompetitiveBinding SitesBreast NeoplasmsCell LineCell NucleusChromatography, AffinityDNADNA-Binding ProteinsFemaleHigh Mobility Group ProteinsHumansImmunoblottingKineticsMacromolecular SubstancesDNADNA-Binding ProteinsHigh Mobility Group ProteinsMacromolecular SubstancesReceptors, Progesterone

Identifiers

PMID8164686
PMCPMC358703
OpenAlexW1837125915

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.